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Age, HLA and antibodies in islet autoimmunity 
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Context: Children with initial autoantibodies to either insulin (IAA) or glutamic acid 
decarboxylase (GADA) differ in peak age of seroconversion and have different type 1 
diabetes (T1D) risk gene associations suggesting heterogeneity in the disease process.  
Objective: To compare the associations of age at seroconversion, HLA risk and specificity of 
secondary autoantibodies with the progression of islet autoimmunity between children with 
either IAA or GADA as their first autoantibody.  
Design and Methods: A cohort of 15,253 children with HLA-associated increased risk of 
T1D participated in a follow-up programme where islet autoantibodies were regularly 
measured. The median follow-up time was 6.7 years. Spearman´s correlation, Kaplan-Meier 
survival plots and Cox proportional-hazard models were used for statistical analyses. 
Results: Persistent positivity for at least one of the tested autoantibodies was detected in 998 
children and 388 of children progressed to clinical T1D. Young age at initial seroconversion 
was associated with a high probability of expansion of IAA-initiated autoimmunity and 
progression to clinical diabetes, whereas expansion of GADA-initiated autoimmunity and 
progression to diabetes were not dependent on initial seroconversion age. The strength of 
HLA risk affected the progression of both IAA- and GADA-initiated autoimmunity. The 
simultaneous appearance of two other autoantibodies increased the rate of progression to 
diabetes compared to that of a single secondary autoantibody among subjects with GADA-
initiated autoimmunity but not among those with IAA as the first autoantibody. 
Conclusions: Findings emphasize the differences in the course of islet autoimmunity 
initiated by either IAA or GADA supporting heterogeneity in the pathogenic process. 
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Young age at initial islet autoantibody seroconversion in childhood associates with a high risk of 
further progression to T1D in IAA-initiated autoimmunity but not in  GADA-initiated autoimmunity. . 
Introduction 
The development of type 1 diabetes (T1D) is usually preceded by the appearance of 
autoantibodies that recognize various autoantigens expressed in the pancreatic islets. 
Autoantibodies targeting insulin (IAA), glutamic acid decarboxylase (GADA) and the IA-2 
antigen (IA-2A) are well characterized and represent the most important predictive markers 
for T1D (1). A marked difference in the T1D risk has been observed in relation to the 
presence of only one of these autoantibodies compared to the presence of two or more 
autoantibodies (2-4). Although substantial variation in the individual progression rate does 
exist, a joint analysis of three prospective follow-up studies suggests that within 15 years 
after the appearance of multiple autoantibodies, the proportion of people with clinical 
diabetes is greater than 80% (5). 
 Both genetic susceptibility, mainly defined by the HLA class II gene region, and 
environmental factors, which remain poorly defined, are important in the development of 
islet autoimmunity and T1D (6). The heterogeneity of the disease process is supported by the 
findings of follow-up studies started early in infancy. In most children who develop islet 
autoimmunity, either IAA or GADA is the first autoantibody to appear alone. IAA as the first 
single autoantibody peaks before the age of 2 years and rapidly becomes rare thereafter, 
whereas GADA as the first single autoantibody peaks at the age of 4-5 years and continues to 
appear at a relatively high level throughout childhood. Genetic markers characterizing IAA-
initiated autoimmunity include the HLA DR4-DQ8 haplotype and the T1D risk-associated 
genotype of the INS gene, whereas the GADA-initiated disease process is related to the 
presence of HLA-DR3-DQ2 and risk markers in the ERBB3/IKZF4 and BACH2 gene regions 
(7-10). 
 In the current analysis, we aimed to compare associations of various factors, such as 
age at seroconversion, HLA risk group and order of appearance of secondary autoantibodies, 
known to affect the expansion of islet autoimmunity and progression to T1D (3,11-13) 
between children who had developed IAA as the first single autoantibody and children who 
had developed GADA as the first single autoantibody. The roles of age at initial 
seroconversion, genetic susceptibility contributed by the HLA class II genotype and the 
specificity of the secondary islet autoantibodies in the disease process were separately 
analysed in children with either IAA or GADA as the initial autoantibody. 
Materials and Methods 
Participants and serum samples  
The DIPP study is an ongoing follow-up study in Finland that has recruited newborn infants 
with increased HLA-associated genetic risk for T1D since November 1994 (7). The present 
analysis is based on information collected from 15,253 children followed from a few months 
of age up to 15 years of age until May 2017 (Table 1). Peripheral blood samples were 
collected either at 3-month intervals until the age of 24 months and at 6-month intervals 
thereafter (one participating centre) or at 3, 6, 12, 18 and 24 months and annually thereafter 
(two participating centres). After initial seroconversion to positivity for islet autoantibodies, 
the follow-up was continued at 3-month intervals. The diagnosis of T1D was confirmed 
based on World Health Organization criteria (14). 
Islet autoantibodies  
In the beginning of the study, classical islet cell antibodies (ICA) defined by 
immunofluorescence were used for screening, and if the child was found to be positive for 
ICA, all serum samples collected from this child were also analysed for IAA, GADA and IA-
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2A. All sera collected from children enrolled since the beginning of 2003 have been tested 
systematically for these three biochemical autoantibodies. Additionally, all sera from a cohort 
of the first 1004 enrolled children who were born between November 1994 and July 1997 
were later analyzed for these three biochemical autoantibodies. The methods used in the 
analyses have been described previously in detail (3). The disease sensitivities and 
specificities of the assays in our laboratory according to the 2002-2015 DASP/IASP 
workshops were 44-50% and 96-99% for IAA, 76-92% and 94-99% for GADA, and 64-76% 
and 97-100% for IA-2A, respectively. Persistent islet autoantibodies were defined by 
detection in two consecutive samples. 
HLA genotyping  
HLA genotyping for selection of the follow-up cohort was performed from cord blood and 
was originally performed using sequence-specific oligonucleotide probes specific for the 
HLA DQB1*02, DQB1*03:01, DQB1*03:02 and DQB1*06:02/3 alleles. Infants with either 
DQB1*02/DQB1*03:02 or DQB1*03:02/x (x≠DQB1*02, DQB1*03:01, DQB1*06:02/3) 
were defined as eligible for the prospective follow-up study. Genotyping was further 
developed during the study period, and the eligibility criteria were modified to obtain 
improved specificity as described previously (7).  
 All study subjects who had developed islet autoantibodies were genotyped using full-
house HLA DR/DQ genotyping whenever a DNA sample was available (968/998). This 
genotyping has been described in detail earlier (15). In short, the common DR-DQ haplotypes 
were defined based on DQB1 typing expanded by typing of DQA1 and DRB1 alleles needed 
to deduce the DR-DQ haplotype present and associated risk for T1D. The DR-DQ haplotypes 
were sorted according to their odds ratio (OR) values based on the comparison of their 
frequencies in 2991 Finnish children with T1D and affected family based artificial controls 
formed by the haplotypes, which were not transmitted to the diabetic child in the families. 
HLA-DRB1*04:01/2/5-DQA1*03-DQB1*03:02 haplotypes were defined to be associated 
with a strong susceptibility (S), DRB1*04:04-DQA1*03-DQB1*03:02 and (DR3)-
DQA1*05-DQB1*02 with a weaker susceptibility (s) whereas (DR15)-DQB1*06:01/2, 
(DR14)-DQB1*05:03 and (DR7)-DQA1*02:01-DQB1*03:03 were defined as strongly 
protective (P) and (DR11/12/13)-DQA1*05-DQB1*03:01, DRB1*04:03- DQA1*03-
DQB1*03:02 and (DR13)-DQB1*06:03 as weakly protective (p) haplotypes. Haplotypes 
defined as neutral (N) included (DR1/10)-DQB1*05:01, (DR13)-DQB1*06:04/9, (DR16)-
DQB1*05:02, (DR4)-DQA1*03-DQB1*03:01, (DR7)-DQA1*02:01-DQB1*02, (DR9)-
DQA1*03-DQB1*03:03, (DR8)-DQB1*04. The DR antigens within parentheses were 
deduced based on fixed combinations within Northern European populations. 
 Genotypes formed by these haplotypes could be classified into six risk groups with 
non-overlapping 95% confidence intervals in OR values. Combinations of DR3 and DR4 
positive (S/s or s/s) risk haplotypes were associated with the highest risk (group 5), other S/s 
than DR3/DR4 combinations, S/S, s/s and S/N with a moderately increased risk (group 4). 
S/p and s/N associated with a slightly increased risk (group 3). N/N, S/P, s/P and s/p 
combinations were classified as neutral (group 2), p/N as slightly decreased risk (group 1) 
and further P/N, p/p, P/p, and P/P as strongly decreased risk (group 0). 
 The more detailed genotyping revealed that a small group of the subjects in the 
follow-up cohort in fact carried genotypes associated with neutral or even decreased risk of 
type 1 diabetes. This conclusion is mainly based on the detection of the DRB1*04:03 allele 
when performing DR4 subtyping of DQB1*03:02-positive subjects and identification of the 
strongly protective but rare (DR7)-DQA1*02:01-DQB1*03:03 and (DR14)-DQB1*05:03 
haplotypes in subjects eligible based on the presence of the DQB1*03:02/x genotype before 
September 2004.  
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Statistical analyses  
Kaplan-Meier survival plots and Cox proportional hazards models were applied to study and 
compare clinical T1D and autoantibody development survival functions in different age- and 
HLA class II genotype groups, as well as IAA- and GADA-initiated models. Participants 
developing persistent biochemical autoantibodies were divided into four age quartiles based 
on the age at the first positive sample: Q1 (0-1.48), Q2 (1.48-2.98), Q3 (2.98-5.09) and Q4 
(5.09-14.2). For survival analyses of HLA-associated genetic risk, the children were 
organized into six HLA risk groups from 0 to 5. Because of the small numbers in the neutral 
or protective genotype groups (0-2) these were combined. The differences between clinical 
T1D and autoantibody development hazard functions were assessed by the log-rank test. The 
correlations between age at initial seroconversion and HLA class II genotypes were 
calculated using the non-parametric Spearman´s test. The statistical significance level was set 
at 0.05 for all two-sided tests. Kaplan-Meier survival plots and Cox proportional-hazard 
models were studied using R version 3.4.3 (https://www.R-project.org/) and the “survival” 
package (https://CRAN.R-project.org/package=survival).  
Results 
Features of the studied population  
The characteristics of the children studied in the follow-up cohort are shown in Table 1. A 
total of 15,253 children with at least three follow-up samples were included in the study, but 
the analyses were performed only among children who seroconverted to positivity for islet 
autoantibodies. Of the total of 998 (402 girls) children who tested positive for at least one 
persistent biochemical autoantibody, 545 (227 girls) developed at least two autoantibodies, 
445 (187 girls) developed three persistent islet autoantibodies and 388 (173 girls) developed 
T1D. In most cases (754/998, 75.5%), a single autoantibody was detected in the first 
autoantibody-positive sample. IAA and GADA were the two most common first 
autoantibodies, 341 (34.2%) children had IAA and 352 (35.3%) GADA as the first 
autoantibody, whereas IA-2A was observed as the first single autoantibody at seroconversion 
in only 61 (6.1%) cases. Analyses comparing the groups with different primary 
autoantibodies were thus performed only for those with either IAA- or GADA-initiated islet 
autoimmunity.  
Effect of age at the initiation of islet autoimmunity on the subsequent appearance of 
autoantibodies and progression to diabetes  
An association between young age at initial seroconversion and rapid expansion of 
autoimmunity was observed in the group with IAA as the first single autoantibody (p = 
5.1×10-11, global p-value from the log-rank test). The initial autoantibody seroconversion in 
the youngest age quartile was associated with a 9.69-fold increased hazard of developing 
multiple autoantibodies compared to Q4. The hazards of secondary autoantibody 
development were increased by factors of 6.59 and 6.74 for Q2 and Q3, respectively. Young 
age at initial seroconversion was also associated with rapid progression to clinical T1D in 
children with IAA-initiated autoimmunity (global p = 5.2×10-8). The initial autoantibody 
seroconversion in the youngest age quartile was linked to a 7.38-fold higher rate of clinical 
T1D than that in the oldest age quartile. The hazard ratios of T1D increased by factors of 4.67 
and 3.14 for the Q2 and Q3 quartiles, respectively, when compared to the oldest age quartile 
(Fig. 1). 
 Only a marginal effect of age at initial seroconversion was observed in children with 
GADA as the first autoantibody (global p = 0.042). The youngest age quartile actually 
developed fewer multiple autoantibodies than the other groups. No age effect on progression 
to clinical diabetes was observed (global p = 0.410) (Fig. 1). 
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Effect of HLA class II genotypes on the subsequent appearance of autoantibodies and 
progression to type 1 diabetes  
The expansion of autoimmunity from a single primary autoantibody to the appearance of 
secondary autoantibodies and progression to T1D was strongly associated with the HLA risk 
group in both children with IAA-initiated autoimmunity (global p = 9.0×10-6 for the 
development of secondary autoantibodies and global p = 7.4×10-6 for progression to T1D) 
and children with GADA-initiated autoimmunity (global p = 0.0001 for the development of 
secondary autoantibodies and global p = 0.002 for progression to T1D). The hazard ratios for 
the development of secondary autoantibodies in different HLA genetic risk groups were 
similar in both IAA- and GADA-initiated models, ranging from the maximum values of 8.65 
(IAA-initiated model) to 6.81 (GADA-initiated model) in risk group 5. 
Correlation between age at initial seroconversion and HLA class II genotypes  
Although both the age at the appearance of the first autoantibody and HLA-associated risk 
had a strong effect on expansion of autoimmunity and progression to diabetes in children 
with IAA-initiated autoimmunity, only a weak correlation was detected between these two 
parameters (Spearman´s ρ = -0.12, p = 0.033, Fig. 2). 
Progression from secondary autoantibodies to type 1 diabetes  
When progression to type 1 diabetes was analysed after the development of secondary islet 
autoantibodies, progression was slightly faster in children with IAA as the first autoantibody 
than in those with GADA-initiated autoimmunity (Fig. 3, global p = 0.021).  
 When the effect of the specificities of secondary autoantibodies was tested among 
those with IAA as the first autoantibody, IA-2A predicted more rapid development of 
diabetes than GADA (HR= 2.06 with a p-value 0.0037), but the further effect of the 
combination of IA-2A and GADA appearing together was not significant compared to that 
associated with IA-2A alone as the second autoantibody (HR= 1.56 with a p-value 0.0947) 
(Fig. 4a). The groups with GADA as the first autoantibody and IAA or IA-2A as the second 
autoantibodies did not differ in their progression rates, but when these antibodies appeared 
together, progression rate to diabetes was strongly enhanced over that of IAA (HR= 5.37 with 
a p-value 0.0001) alone as the secondary autoantibody (Fig. 4b). 
Discussion 
Our study revealed important differences in the autoimmune process classified by the 
specificity of the first single islet autoantibody. The well-established association between 
young age at the appearance of autoantibodies and rapid progression of the autoimmune 
process (11,12,16) was observed only in IAA-initiated autoimmunity. The age at initial 
seroconversion did not influence the subsequent disease course when GADA was the first 
single autoantibody to appear. This finding may indicate that possible environmental effects 
that trigger and promote IAA-initiated disease are present mainly during early life, whereas 
more continuously operative factors are relevant for islet autoimmunity initiated by GADA. 
This finding is also in accordance with the major early peak in the appearance of IAA as the 
first autoantibody and the later age peak and continuous appearance of GADA as the first 
autoantibody through childhood and into adulthood (7,9,10). These differences may also be 
related to the maturation and development of the immune system in early childhood. Age-
associated differences have also been reported in autoantigen-induced cytokine patterns of 
peripheral blood lymphocytes and lymphocyte populations involved in insulitis (17). 
 HLA class II region is the major genetic determinant of T1D, and the HLA-DR/DQ 
genotypes have been used as the basis of genetic screening in multiple prospective follow-up 
studies, including the DIPP study, where the effect of class II HLA risk grading on the 
development of islet autoantibodies has been well documented (15,18). The HLA class II 
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genotype had a very similar effect on the expansion of autoimmunity in children with both 
IAA- and GADA-initiated autoimmunity. HLA risk group-dependent expansion of islet 
autoimmunity took place mainly during the first two years after initial seroconversion.  
 The effect of age on the progression from single to multiple autoantibodies in subjects 
positive for either IAA or GADA was also recently compared in the TrialNet study, with the 
conclusion that in relatives with IAA, the spread of autoimmunity was largely limited to early 
childhood, whereas immune responses initially directed to GADA often also expanded during 
later age (19). The results are thus congruent, but the studies differ strongly in the age 
distribution of single autoantibody-positive subjects, with a mean age of 17.6 years in 
TrialNet and 3.0 years in the DIPP study, and in the relative proportions of subjects with IAA 
or GADA as the first autoantibody; the studies thus complement each other in this respect. 
The large differences in the spread of IAA-initiated autoimmunity among the youngest 
children were well defined in the DIPP study, whereas differences appearing in early 
adulthood in GADA-initiated autoimmunity were well represented in the TrialNet series. 
 The original observation of various age peaks in the appearance of IAA and GADA-
initiated islet autoimmunity was reported in the DIPP study (7) and has been confirmed in the 
BABYDIAB and TEDDY studies (9,10). In the current analysis from the DIPP study we also 
report the different effect of seroconversion age on the progression rate to type 1 diabetes in 
IAA- and GADA-initiated autoimmunity. This represents novel information and has not been 
reported earlier in studies, which have followed up children from birth.  
 The major impact of secondary islet autoantibodies on the probability of T1D 
progression was evident to a similar extent in children with IAA- and GADA-initiated islet 
autoimmunity. However, in children with IAA-initiated autoimmunity, IA-2A, as a secondary 
autoantibody, was associated with slightly faster progression than observed for the GADA-
initiated process. The combination of GADA and IA-2  as secondary autoantibodies did not 
increase the risk of progression compared to that of IA-2A alone in IAA-initiated 
autoimmunity, but interestingly, the combination of IAA and IA-2A radically increased the 
progression rate in children with GADA-initiated autoimmunity compared to the appearance 
of IAA or IA-2A alone as a secondary autoantibody. This observation concerning the 
importance of additional IA-2A compared to the IAA and GADA combination in children 
with GADA-initiated autoimmunity is in accordance with the findings from the Belgian 
Diabetes Registry, in which the majority of the study subjects had GADA as the first 
autoantibody detected (20).  
 Our results provide a new method for estimating disease risk in children who have 
been observed from young age and among whom the initial islet autoantibody has been 
identified. We now know that if IAA is the first autoantibody to appear, the risk of 
progression to diabetes is high in the youngest age groups, but we can conclude that the risk 
decreases rapidly if secondary autoantibodies have not developed within a few years because 
the probability of their appearance decreases thereafter. However, in children with GADA as 
the first autoantibody, the age at initial seroconversion does not affect the probability of 
progression to T1D although also in these subjects, secondary autoantibodies usually appear 
within a few years after the initial seroconversion. After the development of secondary 
autoantibodies, the further progression rate can be estimated to a certain extent based on the 
specificity of these autoantibodies. The level of HLA class II genotype-associated risk affects 
the disease risk caused by the expansion of autoimmunity in children with both IAA-initiated 
and GADA-initiated autoimmunity. 
 This study has some limitations. We had to limit our main comparison to the two 
main groups, those with either IAA or GADA as the first single autoantibody, since the 
number of participants with IA-2A as their first autoantibody was too small for reasonable 
comparisons although the DIPP birth cohort is the largest group of children with increased 
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genetic risk of type 1 diabetes ever recruited to a follow-up study starting from birth and the 
number of children with persistent seroconversion for single or multiple islet autoantibodies 
is also highest reported.  
 The criteria used in HLA class II typing to determine eligibility for the DIPP study 
cover only approximately 60% of genotypes found in children diagnosed with T1D in 
Finland. A considerable proportion of genotypes are thus not included in the DIPP follow-up 
cohort, and DR3-DQ2-positive subjects with a disease risk are especially underrepresented. 
In the DIPP study, autoantibody screening was mainly based on ICA until 2003. Therefore, 
some subjects positive for IAA only were apparently not recognized. Additionally, the visit 
intervals were longer after 2 years of age, which hampered the identification of the first islet 
autoantibody in older children, although this parameter could be defined in the majority of 
the children. Not all of the factors affecting the progression rate to T1D were included in the 
analyses, e.g. the presence of first-degree relatives with T1D, autoantibodies specific for the 
zinc transporter 8 molecule, the levels of islet autoantibodies and their affinities, and data 
from class I HLA alleles and polymorphisms in some non-HLA genes associated with T1D 
(8,21-24).  
 These findings should therefore be further expanded by analyzing also children with a 
lower HLA-inferred risk and subjects developing autoantibodies at an older age. Also, studies 
on the autoantibody levels and affinities as well as studies on the role of ZnT8 autoantibodies 
might bring valuable additional information. In the Belgian Diabetes Register study, ZnT8A 
increased the progression rate over IAA and GADA combination similarly to IA-2A (20) but 
due to lacking ZnT8A data we were not able to confirm this. Information on the presence of 
first-degree relatives with T1D (FDR) might also be useful, although their number among 
newborn children recruited is rather small. In the TEDDY follow-up cohort having a father or 
sibling with T1D was associated with higher risk of developing islet autoantibodies or T1D,  
the effect was similar in the groups of either IAA or GADA as the first autoantibody. Having 
a diabetic sibling was, however, increased only in children with IAA and not in those with 
GADA as the first autoantibody but the numbers of children with T1D siblings was very 
small: only 17 among 252 children with IAA and six in 226 children with GADA as the first 
autoantibody (10). During 2004-2010 when newborn infants were recruited also to the 
TEDDY study the proportion of FDR positive children was systematically registered in the 
DIPP centers and was 4.7% in children eligible for either TEDDY or DIPP.  
 An apparent target of future prevention trials is to stop islet autoimmunity in its early 
phase. When establishing eligibility criteria and case-control matching for such interventions, 
it is essential to take into account factors that are known to affect disease progression. 
Similarly, it is important to include this knowledge in analyses aimed at identifying new 
environmental or other factors that affect the progression of islet autoimmunity and 
development of clinical T1D. 
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Fig. 1 Effect of age at initial seroconversion on spreading of islet autoimmunity from the first 
single autoantibody to multiple autoantibodies in children with either IAA (a) or GADA (b) 
as the first autoantibody, and the effect on the progression from initial seroconversion to 
clinical diabetes in children with either IAA (c) or GADA (d) as the first autoantibody. 
Number of observations, number of events, the restricted mean survival, hazard ratio and its 
95% confidence interval with the log-rank test p-values are presented. 
Fig. 2 Correlation between age at seroconversion for IAA as the first autoantibody and HLA 
class II risk grade. Spearman´s ρ = -0.12, p = 0.033. 
Fig. 3 Type 1 diabetes-free survival after the appearance of the second autoantibody, in IAA-
and GADA-initiated models. Number of observations, number of events, the restricted mean 
survival, hazard ratio and its 95% confidence interval with the log-rank test p-values are 
presented. 
Fig. 4 Specificity of secondary autoantibodies and progression to clinical diabetes when (a) 
IAA is the first autoantibody. The second autoantibodies after IAA are either GADA, IA-2A, 
or IA-2A and GADA (IA-2A:GADA). (b) Specificity of secondary autoantibodies and 
progression to clinical diabetes when GADA is the first autoantibody. The second 
autoantibodies after GADA are either IAA, IA-2A, or IAA and IA2A (IAA:IA2A). Number 
of observations, number of events, the restricted mean survival, hazard ratio and its 95% 
confidence interval with the log-rank test p-values are presented. 
Table 1. Description of the study subjects 
Characteristic Value 
Total number of children in follow-up 15,253 
Girls 6,965 (45.7%) 
Median follow-up time, years (interquartile range) 6.7 (2.75-12.75) 
Developed autoantibodies (aab) 
at least one aab / Girls 998 / 402 (40.3%) 
at least two aabs / Girls 545 / 227 (41.7%) 
at least three aabs / Girls 445 / 187 (42%) 
IAA as the first aab 341 (34.2%) 
IA-2A as the first aab 61 (6.1%) 
GADA as the first aab 352 (35.3%) 
Multiple aabs at initial seroconversion / Girls 244 / 99 (40.6%) 
Median age at initial aab seroconversion (interquartile range) 3.0 (1.48-5.1) 
Median follow-up time after initial aab seroconversion, years (range) 3.7 (0.0-14.2) 
HLA-DR/DQ genotype-associated risk 
High risk (5) 243 (25.1%) 
Moderately increased risk (4) 503 (52.0%) 
Slightly increased risk (3) 184 (19.0%) 
Neutral (2) 27 (2.8%) 
Slightly decreased risk (1) 8 (0.8%) 
Strongly decreased risk (0) 3 (0.3%) 
Incomplete typing  30 
Together 998 
Developed type 1 diabetes after aab seroconversion  388 
Girls 173 (44.6%) 
Median age at diagnosis, years (interquartile range) 6.0 (3.47-9.66) 
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